ASIT Biotech S.A., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead compound is gp-ASIT+, a phase III trial for the treatment of grass pollen allergy administered by subcutaneous injections. It also develops hdm-ASIT+ for the treatment of house dust mite rhinitis; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as BioTech Tools SA and changed its name to ASIT Biotech S.A. in August 2015. ASIT Biotech S.A. was founded in 1997 and is based in Woluwe-Saint-Lambert, Belgium.